Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Holding MYGN?
Track your performance easily
MYGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.82 - $29.30
Previous Close$28.47
Volume665.04K
Average Volume (3M)777.40K
Market Cap
$2.59B
Enterprise Value$2.63B
Total Cash (Recent Filing)$97.30M
Total Debt (Recent Filing)$143.30M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Oct 29, 2024EPS Estimate
$0.02Last Dividend Ex-Date
Jun 15, 2009Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding90,820,354
10 Day Avg. Volume667,591
30 Day Avg. Volume777,398
Standard Deviation0.16
R-Squared0.39
Alpha-0.00828
Financial Highlights & Ratios
Price to Book (P/B)3.49
Price to Sales (P/S)3.24
Price to Cash Flow (P/CF)249.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.28
Enterprise Value/Gross Profit5.09
Enterprise Value/Ebitda-37.22
Forecast
1Y Price Target
$31.67Price Target Upside11.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Myriad Genetics News
Bulls Say, Bears Say
Bulls Say
Operational PerformanceHereditary cancer testing and GeneSight both posted strong performance.
ProfitabilityThe company has made considerable progress transforming for profitable growth by divesting non-core assets and improving the doctor/patient experience.
Revenue GrowthManagement raised its long-term revenue growth target to 12%, reflecting consistent outperformance and favorable industry trends.
Bears Say
Control Group IssuesThe announcement that MYGN does not have a viable control group and will discontinue the portion of its study utilizing a control group could be a negative catalyst.
Investor ConcernsMYGN's disclosure of the study discontinuation in an 8-K might raise questions among investors.
Study DiscontinuationMYGN is discontinuing Phase 2 of its economic impact study on GeneSight due to the inability to find an adequate control group.
---
Ownership Overview
7.67% Insiders
26.28% Mutual Funds
52.94% Other Institutional Investors
13.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $13.82 and its highest was $29.30 in the past 12 months.
What is Myriad Genetics’s market cap?
Currently, no data Available
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Oct 29, 2024 which is in 39 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Aug 06, 2024. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.062.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is $0.02.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 90,820,350 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 2.619%.
Which hedge fund is a major shareholder of Myriad Genetics?
Among the largest hedge funds holding Myriad Genetics’s share is Glenview Capital Management LLC. It holds Myriad Genetics’s shares valued at 92M.
---
Myriad Genetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.67 (11.95% Upside)
$31.67 (11.95% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $646.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.17%
12-Months-Change
Fundamentals
Return on Equity
-21.03%
Trailing 12-Months
Asset Growth
-8.60%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
---
MYGN Company Deck
---
MYGN Earnings Call
Q2 2024
0:00 / 0:00
---
MYGN Stock 12 Month Forecast
Average Price Target
$31.67
▲(11.95% Upside)
Technical Analysis
Best Analysts Covering MYGN
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+21.51%
reiterated a buy rating 8 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +21.51% per trade.
---